Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 11/20 | 0.60 |
| ▸ | IL2 | P60568 | 11/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.54 |
| ▸ | TNF | P01375 | 1/20 | 0.54 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.52 |
| ▸ | FLT3 | P36888 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | DDO | Q99489 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24447917 | 0.87 | ALB (0.55) | ALBIL2MEN1KMT2ARCE1 | |
| SCHEMBL17149706 | 0.85 | KMT2A (0.71) | ALBIL2MEN1KMT2ARCE1 | |
| SCHEMBL17149707 | 0.85 | KMT2A (0.71) | ALBIL2MEN1KMT2ARCE1 | |
| SCHEMBL24446999 | 0.85 | ALB (0.56) | ALBIL2TNF | |
| SCHEMBL24019707 | 0.84 | MEN1 (0.55) | ALBIL2MEN1KMT2ARCE1 | |
| SCHEMBL24019963 | 0.84 | MEN1 (0.55) | ALBIL2MEN1KMT2ARCE1 | |
| SCHEMBL30147706 | 0.84 | HRH4 (0.56) | ALBIL2TNFHRH4FLT3 | |
| SCHEMBL24019955 | 0.83 | ALOX15 (0.57) | ALBIL2MEN1KMT2ARCE1 | |
| SCHEMBL24448418 | 0.82 | ALB (0.68) | ALBIL2TNF | |
| SCHEMBL29655561 | 0.82 | ALB (0.68) | ALBIL2TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-11524940-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2022-12-13 | — | — | US | disclosed |
| US-11174231-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174231-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | ALB 3662/4885IL2 3710/4885MEN1 4164/4885 |
| US-11524940-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | ALB 3662/4885IL2 3710/4885MEN1 4164/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | ALB 3935/4885IL2 2376/4885MEN1 4306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.